• Type:
  • Category:

BRAIN Biotech AG Financial Results 9M 2022 | Unveiling the Future with IR



This video features Michael Schneiders, Head of Investor Relations at Brain Biotech AG.


Join us as Michael takes us through Brain’s Financials Q3-2022 Presentation. He will cover a range of topics, including Brain’s core values, their commitment to ESG and sustainability, Q3 highlights and lowlights, incubator exits, PHA121, the Brain incubator, financial highlights for 9M 2021/22, cash and cash flow, long-term revenue growth trajectory, risks related to supply chain and inflation, and FY21/22 guidance and mid-term targets.


So sit back, relax, and let Michael guide you through Brain’s latest developments.

Company Profile

BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group’s business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.


The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.


As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.


Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

BRAIN Biotech AG

Darmstaedter Strasse 34-36
64673 Zwingenberg, Germany

phone +49 6251 9331 86


  • Brain at a Glance
  • Brain Core Values
  • ESG / Sustainability
  • Q3-Highlights / Lowlights
  • Incubator Exits
  • PHA121
  • Brain Incubator
  • 9M 2021/22 Financial Highlights
  • Cash & Cash Flow
  • Long-Term Revenue Growth Trajectory
  • Risks: Supply Chain and Inflation
  • FY21/22 Guidance, Mid-Term Targets



Michael Schneiders
CFO | BRAIN Biotech AG​



This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Company Presentations

More Elevator Pitches

Reviews for BRAIN Biotech AG Financial Results 9M 2022 | Unveiling the Future with IR

There are currently no reviews for BRAIN Biotech AG Financial Results 9M 2022 | Unveiling the Future with IR
Scroll to top